Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | ADH5 | P11766 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8292811 | 0.90 | XDH (0.59) | XDHMAPTTDP1MEN1KMT2A | |
| SCHEMBL25216798 | 0.84 | XDH (0.59) | XDHMAPTTDP1MEN1KMT2A | |
| SCHEMBL30955240 | 0.80 | ALDH1A1 (0.67) | XDHMAPTALDH1A1ADH5 | |
| SCHEMBL25387562 | 0.80 | XDH (0.55) | XDHMAPTTDP1MEN1KMT2A | |
| SCHEMBL1250484 | 0.79 | XDH (1.00) | XDHMEN1KMT2ANPSR1KDM4E | |
| SCHEMBL737722 | 0.78 | MAPT (1.00) | MAPTTDP1MEN1KMT2APOLB | |
| SCHEMBL29409289 | 0.78 | MAPT (1.00) | MAPTTDP1MEN1KMT2APOLB | |
| Hydrochloric Acid SCHEMBL2157978 | 0.77 | TDP1 (0.70) | XDHMAPTTDP1MEN1KMT2A | |
| SCHEMBL2653775 | 0.77 | XDH (0.67) | XDHMAPTMEN1KMT2ALMNA | |
| SCHEMBL17834028 | 0.76 | XDH (0.70) | XDHMAPTMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150360147-A1 | Benzimidazole Compounds And Their Use As Chromatographic Ligands | MILLIPORE (U.K.) LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| US-9144757-B2 | Benzimidazole compounds and their use as chromatographic ligands | MILLIPORE (U.K.) LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| US-20150087821-A1 | Benzimidazole Compounds And Their Use As Chromatographic Ligands | MILLIPORE (U.K.) LIMITED (GB) | 2015-03-26 | — | — | US | disclosed |
| US-8933206-B2 | Benzimidazole compounds and their use as chromatographic ligands | MILLIPORE (U.K.) LIMITED (GB) | 2015-01-13 | — | — | US | disclosed |
| CN-101220077-B | Benzimidazole compounds and their use as chromatographic ligands | MILLIPORE U K LTD | 2013-06-05 | — | — | CN | disclosed |
| EP-1944311-B1 | Benzimidazole compounds and their use as chromatographic ligands for the isolation of immunoglobulins | MILLIPORE UK LTD (GB) | 2012-06-06 | — | — | EP | disclosed |
| EP-2341064-A1 | Benzimidazole compounds and their use as chromatographic ligands | Millipore (U.K.) Ltd. (GB) | 2011-07-06 | — | — | EP | disclosed |
| US-20080262207-A1 | For isolation of immunoglobulins; solid phase agarose matrices | MILLIPORE (U.K.) LIMITED (GB) | 2008-10-23 | — | — | US | disclosed |
| EP-1944311-A1 | Benzimidazole compounds and their use as chromatographic ligands | Millipore (UK) Limited (GB) | 2008-07-16 | — | — | EP | disclosed |
| CN-101220077-A | Benzimidazole compounds and their use as chromatographic ligands | MILLIPORE UK LTD (GB) | 2008-07-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087821-A1 | Benzimidazole Compounds And Their Use As Chromatographic Ligands | IGSF11, IGLV6-57, MRPS34 | XDH 2514/4885MAPT 4225/4885TDP1 4832/4885 |
| US-20080262207-A1 | For isolation of immunoglobulins; solid phase agarose matrices | IGSF11, LY96, IGLV6-57 | XDH 2894/4885MAPT 3950/4885TDP1 4549/4885 |
| US-20150360147-A1 | Benzimidazole Compounds And Their Use As Chromatographic Ligands | IGSF11, IGLV6-57, MRPS34 | XDH 2514/4885MAPT 4225/4885TDP1 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.